Article

AMO names new president, Randy Meier

Santa Ana, CA-Richard "Randy" A. Meier has been named president of Advanced Medical Optics Inc. (AMO), effective Nov. 19

Santa Ana, CA-Richard “Randy” A. Meier has been named president of Advanced Medical Optics Inc. (AMO), effective Nov. 19. He retains his existing chief operating officer (COO) title and responsibilities, which include leadership of the company’s eye care and cataract/implant businesses, global customer services, and manufacturing operations.

James V. Mazzo, previous holder of the title of president, remains the company’s chairman and chief executive officer.

“Randy has assumed increasingly broad leadership roles since our spin-off [from Allergan] in 2002 and, over that time, has played an integral role in the growth and development of our company,” said Mazzo. “I am confident in his ability to serve as president, continuing to work closely with me and the AMO leadership team to execute our strategy and deliver on our operational and financial goals.”

Meier joined AMO in 2002 as corporate vice president and chief financial officer (CFO). Subsequently, he held various positions, including executive vice president, operations, and president, eye-care business. In February, he was named COO and CFO, a position he held until October, when Michael Lambert joined the company as CFO.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.